European Patent Office Grants Tenax Therapeutics Landmark Patent for Levosimendan in PH-HFpEF, Paving Way for European Phase 3 Expansion
Thursday, November 13, 2025
On November 13, 2025, Tenax Therapeutics announced a major milestone for its cardiovascular drug development portfolio, signaling a strategic expansion of European clinical and commercial operations. The European Patent Office (EPO) has officially notified the company of its intention to grant a landmark patent for "levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)," covering a broad range of doses and combination uses with other cardiovascular agents. This patent, upon final issuance, secures intellectual property rights for the molecule and its therapeutic application in Europe until at least December 2040, with supplementary protection certificates (SPC) potentially extending its commercial exclusivity even further.
This development is highly significant for European pharma stakeholders seeking novel interventions to address PH-HFpEF—a disease area with high unmet need, substantial morbidity, and limited effective treatments. The patent fortifies Tenax’s competitive position within the European market, ensuring exclusivity for a first-in-class approach in a space where regulatory approval, reimbursement, and widespread adoption depend on both clinical validation and strong IP protection. The patent’s broad claims not only encompass multiple levosimendan dosing strategies but also its use alongside other cardiovascular agents, enabling a flexible clinical and commercial strategy adaptable to diverse healthcare systems and patient needs across the continent.
Tenax’s flagship candidate, TNX-103, has shown promising results in ongoing trials and is progressing towards pivotal studies. In the third quarter corporate update, Tenax confirmed plans to commence the LEVEL-2 global Phase 3 trial this year, specifically targeting Europe with 160+ investigative sites already qualified across 15 countries. The LEVEL studies, designed with robust clinical endpoints and multinational collaboration, represent a coordinated effort to position TNX-103 for regulatory filings with both the EMA and other authorities.
From a business strategy perspective, this patent grant not only de-risks Tenax’s late-phase clinical development activities but also increases the asset’s appeal to potential European licensees, strategic partners, and institutional investors eager to invest in scalable, IP-protected innovation. The prospect of SPC extension further enhances the long-term commercial opportunity, ensuring manufacturers, distributors, and partners have solid grounds to plan manufacturing, distribution, and market access strategies well into the next decade.
Industry experts anticipate that the move might stimulate further B2B partnerships in the European cardiovascular space, ushering in collaborations aimed at advancing the clinical program, optimizing manufacturing, and preparing for launch readiness under EMA regulatory frameworks. The active site qualification process and regulatory interactions across 15 European countries demonstrate an advanced level of operational sophistication, aligning with evolving compliance, pharmacovigilance, and post-marketing surveillance requirements.
In summary, Tenax Therapeutics’ EPO patent grant for levosimendan in PH-HFpEF is not merely an R&D update but a strategically pivotal event for European pharma, directly impacting ongoing clinical trials, partnering dynamics, IP-driven market access, and long-term value creation in one of the region’s most challenging therapeutic landscapes.
